| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 10/03/2006 | US7115360 Isolation and use of solid tumor stem cells |
| 10/03/2006 | US7115272 Polypeptide comprising the immunogenic portion of wilms' tumor suppressor gene(wt1); tumor-associated antigen for use in cancer immunotherapy |
| 10/03/2006 | US7115271 Protein D—an IgD-binding protein of Haemophilus influenzae |
| 10/03/2006 | US7115270 Smallpox vaccine |
| 10/03/2006 | US7115269 Dna vaccines; genetic engineering; eukaroytic gene expression; screening libraries |
| 10/03/2006 | US7115268 Peptides derived from homologous sequences of the family of staphylococcal and streptococcal toxins, which may be polymeric, that provide protection against, or reduce the severity of toxic shock and septic shock from bacterial infections |
| 10/03/2006 | US7115267 polypeptide comprising hemoglobin alpha chain wherein the C-terminal hydrophobic domain has been substituted or deleted; regulating stem cell cycle and accelerating the post-chemotherapy peripheral blood cell recovery; inhibitors and stimulators of stem cell proliferation. |
| 10/03/2006 | US7115266 Angiotensin peptide-carrier conjugates and uses thereof |
| 10/03/2006 | US7115265 Delivering a reagent to a glioblastoma by contacting glioblastoma cells with a reagent (especially an anticancer agent) conjugated to an antibody that specifically binds to an extracellular epitope of glycoprotein (transmembrane) nmb (GPNMB) with a specific sequence |
| 10/03/2006 | US7115264 Monoclonal antibodies to the fibronectin binding protein and method of use in treating or preventing infections |
| 10/03/2006 | US7115263 Compositions and methods for treating hyperimmune response in the eye |
| 10/03/2006 | US7115262 Chimeric protein for prevention and treatment of HIV infection |
| 10/03/2006 | US7115261 Combination of an alpha v beta 3 angiogenisis antagonist and an anti-tumor immunotherapeutic agent, which is a fusion protein of a cytokine IL-2 and an Ig heavy chain that immunoreacts with a tumor associated antigen target. |
| 10/03/2006 | US7115260 Interleukin-1β converting enzyme like apoptotic protease-6 |
| 10/03/2006 | CA2250906C Enteric-coated pharmaceutical compositions of mycophenolate |
| 09/28/2006 | WO2006102557A2 Treatment of protein degradation disorders |
| 09/28/2006 | WO2006102272A2 Methods for treating tumors and cancerous tissues |
| 09/28/2006 | WO2006102098A2 Immunogens for vaccines against antigenically variable pathogens and diseases |
| 09/28/2006 | WO2006102095A2 Framework-shuffling of antibodies |
| 09/28/2006 | WO2006101891A2 Antigens targeted by pathogenic t cells in type 1 diabetes and uses thereof |
| 09/28/2006 | WO2006101692A1 Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
| 09/28/2006 | WO2006101691A1 Therapy of prostate cancer with ctla4 antibodies and hormonal therapy |
| 09/28/2006 | WO2006101487A1 Production and therapeutic uses of th1-like regulatory t cells |
| 09/28/2006 | WO2006101273A1 Prophylactic/therapeutic agent for cancer |
| 09/28/2006 | WO2006100681A2 Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses |
| 09/28/2006 | WO2006100679A2 Recombinant antibodies against human type ii transglutaminase and uses thereof |
| 09/28/2006 | WO2006100582A1 Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function |
| 09/28/2006 | WO2006100449A1 Improvements in or relating to treatment and prevention of viral infections |
| 09/28/2006 | WO2006100430A2 Polypeptides |
| 09/28/2006 | WO2006100257A2 Vaccine and antibodies against parasitic nematodes |
| 09/28/2006 | WO2006100111A1 Composition |
| 09/28/2006 | WO2006100110A1 Novel composition |
| 09/28/2006 | WO2006100109A1 Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response |
| 09/28/2006 | WO2006100108A1 Fermentation process for the production of diphtheria toxin |
| 09/28/2006 | WO2006100089A2 Identification of surface-associated antigens for tumor diagnosis and therapy |
| 09/28/2006 | WO2006099875A1 Antibodies against cd38 for treatment of multiple myeloma |
| 09/28/2006 | WO2006099747A1 Method for isolation of soluble polypeptides |
| 09/28/2006 | WO2006099721A1 Mhc class ii as a preventive vaccine against hiv infection |
| 09/28/2006 | WO2006099698A2 Novel anti-plgf antibody |
| 09/28/2006 | WO2006085910A3 Endotoxin-free moraxella catarrhalis |
| 09/28/2006 | WO2006082328A3 Compositions comprising dehydrated micro-organisms, method for preparing same, and uses thereof |
| 09/28/2006 | WO2006078975A3 Improved vaccine against feline calicivirus |
| 09/28/2006 | WO2006077101A3 Ager-peptides and use thereof |
| 09/28/2006 | WO2006061258A3 Cytotoxic agents comprising new taxanes |
| 09/28/2006 | WO2006034320A3 Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine |
| 09/28/2006 | WO2006023629A3 Treatment of pediatric multiple sclerosis |
| 09/28/2006 | WO2005072214A3 Improved inactivated fcv vaccines |
| 09/28/2006 | WO2005065718A8 Antitumour treatments with metxia-p450 and cyclophosphamide or 5t4 vaccine |
| 09/28/2006 | WO2005054434A3 Use of notch pathway interfering agents for treatment of plasma cell disorders |
| 09/28/2006 | WO2005047315A3 Optimized expression of hpv 58 l1 in yeast |
| 09/28/2006 | WO2005028622A3 Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions |
| 09/28/2006 | WO2004104173A3 Ovr115 ANTIBODY COMPOSITION AND METHODS OF USE |
| 09/28/2006 | WO2004024090A3 Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
| 09/28/2006 | WO2003057857A3 Antibodies directed to pdgfd and uses thereof |
| 09/28/2006 | WO2002008267A9 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 09/28/2006 | US20060217531 Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| 09/28/2006 | US20060217359 Therapeutic procedures |
| 09/28/2006 | US20060217341 DNA vaccine formulations |
| 09/28/2006 | US20060217338 Influenza nucleic acids, polypeptides, and uses thereof |
| 09/28/2006 | US20060217298 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
| 09/28/2006 | US20060217297 Dimerized peptide |
| 09/28/2006 | US20060216808 Isolated, recombinantly produced, enzymatically active hyaluronan synthase; a single protein that is a dual-action catalyst that utilizes UDP-GlcA and UDP-GlcNAc to synthesize hyaluronic acid |
| 09/28/2006 | US20060216794 Hyaluronan synthase gene and uses thereof |
| 09/28/2006 | US20060216793 Culturing Bacillus strain with purified nucleic acid segment having coding region encoding enzymatically active hyaluronan synthase to produce hyaluronic acid; genetic engineering |
| 09/28/2006 | US20060216758 Antibodies to transferrin receptor-like proteins |
| 09/28/2006 | US20060216732 drug screening; identifying a therapeutic for decreasing intraocular pressure raised due to frizzled related protein (FRP) overexpression; contacting a trabecular meshwork cell expressing a Wnt pathway component or a frizzled related protein gene product with a test compound |
| 09/28/2006 | US20060216702 Virus-like particles, methods of preparation, and immunogenic compositions |
| 09/28/2006 | US20060216691 contacting MHC/HLA molecule with a pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to MHC/HLA molecule binds to such MHC/HLA molecule and form a complex, detecting the complexe, assaying the complex in a T cell assay for T cell activation capacity, assaying T cell epitopes |
| 09/28/2006 | US20060216342 Micelle delivery system loaded with a pharmaceutical agent |
| 09/28/2006 | US20060216316 Natural Killer T (NKT) cells; modulating immune responses, such as anti-cancer responses, and enhancing memory responses |
| 09/28/2006 | US20060216315 Cockroach allergen gene expression and delivery systems and uses |
| 09/28/2006 | US20060216314 Hypoallergenic allergy vaccines based on the timothy grass pollen allergen phl p7 |
| 09/28/2006 | US20060216313 treating a urethral stricture by administering the toxin directly to the urethra, for example by use of a stent from which the botulinum toxin can elute or diffuse, |
| 09/28/2006 | US20060216312 Mutants of replication competent vaccinia virus |
| 09/28/2006 | US20060216311 Method and compositions for conferring viral immunity and reversing viral pathogenesis via strategic infection with a theravirus thereby providing genomic integration of genetically engineered, replication incompetent, integrating viral DNA |
| 09/28/2006 | US20060216310 administering to mammal more than one dose of a composition comprising live Newcastle Disease Virus in an amount sufficient to cause tumor regression |
| 09/28/2006 | US20060216309 Identification of genes |
| 09/28/2006 | US20060216308 Genomic sequence that encode ptorprotein; drug for prevention, therapy of infections; induce immunology response |
| 09/28/2006 | US20060216307 Vaccine composition |
| 09/28/2006 | US20060216306 Epitopes of human immunodeficiency virus-1 |
| 09/28/2006 | US20060216305 Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use |
| 09/28/2006 | US20060216304 Rapid, efficient purification of HSV-specific T-lymphocytes and HSV antigens identified via same |
| 09/28/2006 | US20060216303 Processes and products with modified antibodies of human milk fat globule specificity |
| 09/28/2006 | US20060216302 Immunological markers |
| 09/28/2006 | US20060216301 Kdr peptides and vaccines containing the same |
| 09/28/2006 | US20060216300 Recombinant antibodies and compositions and methods for making and using the same |
| 09/28/2006 | US20060216299 Cell cycle targets and peptides |
| 09/28/2006 | US20060216298 Plasmodium falciparum antigens inducing protective antibodies |
| 09/28/2006 | US20060216297 Method and composition for reducing blood sugar levels or fat storage by targeting cathepsin |
| 09/28/2006 | US20060216296 Compositions and methods for promoting or inhibiting angiogenesis |
| 09/28/2006 | US20060216295 Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy |
| 09/28/2006 | US20060216294 Method of modulation |
| 09/28/2006 | US20060216293 TNFalpha-neutralizing antibodies |
| 09/28/2006 | US20060216292 Treatment of neurodegenerative diseases |
| 09/28/2006 | US20060216291 Glycoprotein VI and uses thereof |
| 09/28/2006 | US20060216290 Diagnostics and therapeutics for diseases associated with g-protein coupled protease activated receptor 1 (Par1) |
| 09/28/2006 | US20060216289 GFRalpha3 and its uses |
| 09/28/2006 | US20060216288 An anti-EGFR antibody such as Erbitux or panitumumab in combination with a VEGFR inhibitor such as vatalanib, sunitinib, erlotinib, or motesanib |
| 09/28/2006 | US20060216287 EPH-like receptor protein tyrosine kinases |
| 09/28/2006 | US20060216286 Novel screening method |